B2BROKER Launches cTrader Support & Maintenance Service
14.2.2025 09:46:00 CET | Business Wire | Press release
B2BROKER, a leading liquidity and technology provider, has expanded its services with a new cTrader support and maintenance solution, complementing its existing MT4 and MT5 service offerings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211557945/en/
B2BROKER, a multi-asset liquidity and technology provider, announces the release of its cTrader support and maintenance service. The cTrader Service offers setup, ongoing maintenance, and comprehensive support for your cTrader server, saving you time and financial resources. (Graphic: Business Wire)
cTrader is a widely used multi-asset FOREX/CFD trading platform. Over 300 brokers use it, and adoption is expected to reach 80%. However, high maintenance costs and lengthy team training—often taking up to six months—can pose challenges for brokers.
B2BROKER’s cTrader service solution provides comprehensive technical support and expert dealing training, enabling brokers to streamline operations, reduce costs, and focus on growth.
Notably, clients with an existing cTrader server can benefit from a comprehensive audit service, including a full review of current settings, optimisation recommendations, and seamless transition preparation for B2BROKER’s maintenance.
Here’s a breakdown of the core features included in B2BROKER’s cTrader service:
- Platform configurations
- Server support
- Settings control
- Trading conditions changes
- Symbol sessions modification
- Logs review
Why Choose B2BROKER’s cTrader Service?
B2BROKER’s cTrader service offers a superior alternative to in-house management, providing brokers with expert support, cost savings, and seamless operations.
With extensive expertise in configuring and customising cTrader, B2BROKER’s specialists ensure faster setup, optimised performance, and reduced training requirements—far exceeding the capabilities of most internal teams. This allows brokers to streamline operations without the burden of additional staffing.
The service is also highly cost-effective, offering a more affordable solution than maintaining a full-time in-house team. Clients benefit from 24/7 support and continuous monitoring, ensuring platform stability and peak performance at all times.
B2BROKER takes full responsibility for server infrastructure, employing proactive measures and automated solutions to maintain system reliability and swiftly resolve any issues, keeping trading operations smooth and uninterrupted.
Other benefits of choosing B2BROKER include:
- Team of Market Experts: B2BROKER’s team is continuously on track with the most recent cTrader updates and best practices.
- On-call Systems: Customised support levels with proactive tools that guarantee the quickest resolution to any issue.
- Risk Management Assistance: B2BROKER offers advanced systems for setting risk limits on trading accounts and provides tailored suggestions to every business needs.
- Direct Communication: Brokers can enjoy direct communication channels with cTrader managers to efficiently deal with all necessary liaisons.
- Extended Knowledge Base: Clients can access valuable resources for continuous learning and support, including Zendesk Knowledge Base and a dedicated YouTube channel.
- Training Services: B2BROKER’s team will train the client’s technicians in all aspects of platform customisation and remain available for consultations.
One Solution That Suits All Business Models
B2BROKER recognises that every trading business has unique requirements. Therefore, whether a broker operates independently with cTrader technology or as a standalone entity, B2BROKER offers flexible service plans tailored to diverse business models, ensuring optimised performance and expert support.
“We’ve been in the trading technology field for over a decade, growing alongside our partners at Spotware, the creators of cTrader. We were among the first to launch a cTrader white label solution, and we've recently added a cTrader prop trading white label solution to our offerings. I'm proud to say that our long-standing relationship with Spotware's excellent team enables us to guarantee outstanding service.
“Let us take care of everything—from the setup to the daily management of your cTrader servers—so you can focus on achieving your business goals with confidence.”
Arthur Azizov, CEO & Founder of B2BROKER
Start with B2BROKER’s Professional cTrader Service
Choosing B2BROKER’s cTrader maintenance offers professional service to the trading platform, allowing brokers to focus on core business activities and ensuring that all operations are managed by comprehensive support and advanced tools.
Learn more about B2BROKER’s cTrader server service here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211557945/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom